𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Huntington's disease–like 2 (HDL2) in North America and Japan

✍ Scribed by Russell L. Margolis; Susan E. Holmes; Adam Rosenblatt; Lisa Gourley; Elizabeth O'Hearn; Christopher A. Ross; William K. Seltzer; Ruth H. Walker; Tetsuo Ashizawa; Astrid Rasmussen; Michael Hayden; Elisabeth W. Almqvist; Juliette Harris; Stanley Fahn; Marcy E. MacDonald; Jayalakshmi Mysore; Takayoshi Shimohata; Shoji Tsuji; Nicholas Potter; Kazuhiro Nakaso; Yoshiki Adachi; Kenji Nakashima; Thomas Bird; Amanda Krause; Penny Greenstein

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
90 KB
Volume
56
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Huntington's Disease–like 2 (HDL2) is a progressive, autosomal dominant, neurodegenerative disorder with marked clinical and pathological similarities to Huntington's disease (HD). The causal mutation is a CTG/CAG expansion mutation on chromosome 16q24.3, in a variably spliced exon of junctophilin‐3. The frequency of HDL2 was determined in nine independent series of patients referred for HD testing or selected for the presence of an HD‐like phenotype in North America or Japan. The repeat length, ancestry, and age of onset of all North American HDL2 cases were determined. The results show that HDL2 is very rare, with a frequency of 0 to 15% among patients in the nine case series with an HD‐like presentation who do not have the HD mutation. HDL2 is predominantly, and perhaps exclusively, found in individuals of African ancestry. Repeat expansions ranged from 44 to 57 triplets, with length instability in maternal transmission detected in a repeat of 33 triplets. A younger age of onset is correlated with a longer repeat length (r^2^ = 0.29, p = 0.0098). The results further support the evidence that the repeat expansion at the chromosome 16q24.3 locus is the direct cause of HDL2 and provide preliminary guidelines for the genetic testing of patients with an HD‐like phenotype. Ann Neurol 2004

An Erratum has been published for this article in Ann Neurol 56: 911, 2004.

📜 SIMILAR VOLUMES

Huntington's disease-like 2 in Brazil—Re
Huntington's disease-like 2 in Brazil—Report of 4 patients
✍ Guilherme G. Riccioppo Rodrigues; Ruth H. Walker; Alexis Brice; Cécile Cazeneuve 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 225 KB

## Abstract Huntington's disease‐like 2 (HDL2) is a neurodegenerative disorder found in people of African ancestry with clinical, radiological, and neuropathological manifestations similar to Huntington's disease (HD). HDL2 is caused by a pathological expansion of CAG/CTG triplets in exon 2A of the

Germline mutations in the Von Hippel-Lin
Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan
✍ Berton Zbar; Takeshi Kishida; Fan Chen; Laura Schmidt; Eamonn R. Maher; Frances 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 917 KB

Germline mutation analysis was performed in 469 VHL families from North America, Europe, and Japan. Germline mutations were identified in 3001469 (63%) of the families tested; 137 distinct intragenic germline mutations were detected. Most of the germline VHL mutations (124/137) occurred in 1-2 famil

Objective assessment of motor slowness i
Objective assessment of motor slowness in Huntington's disease: Clinical correlates and 2-year follow-up
✍ Jeroen P.P. van Vugt; Karlijne K.E. Piet; Liesbeth J. Vink; Sabine Siesling; Aei 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB

## Abstract Functional disability of patients with Huntington's disease (HD) is determined by impairment of voluntary motor function rather than the presence of chorea. However, only few attempts have been made to quantify this motor impairment. By using a simple reaction time paradigm, we measured